#genotype 3

Sofosbuvir-based regimens were well tolerated and cure rates were high in this population.

Researchers pooled data from numerous real-world cohorts from various nations.

Genotype 3 of hepatitis C virus is typically difficult to treat.

The investigational glecaprevir/pibrentasvir performed very well among the historically hard-to-treat group, including those with cirrhosis.

Liver fibrosis progresses as people with genotype 3 of hepatitis C virus (HCV) get older, adding urgency to the need for treatment.

ABT-493 and ABT-530, with or without ribavirin, showed promise among those with genotype 3 of hepatitis C in two small trials.

AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3.

The U.S. Food and Drug Administration has approved the combination of Bristol-Myers Squibb’s NS5A inhibitor Daklinza with Gilead Sciences’ Sov...

The FDA approved two more drugs to treat hepatitis C: Daklinza (daclatasvir) for use with sofosbuvir to treat patients with genotype 3

The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

An examination of options for hepatitis C patients with genotype 3, especially for those who failed prior treatment

Daclatasvir and Sovaldi, with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatiti...

Eight weeks of Merck’s grazoprevir/elbasvir, plus Gilead Science’ Sovaldi cured high rates of people with genotype 1 or 3 of hepatitis C.

Twelve weeks of Sovaldi (sofosbuvir), interferon and ribavirin cured 93 percent of people with the difficult-to-treat genotype 3 of hepatitis...

Treating people with genotypes 2 and 3 of hepatitis C is cost effective in some circumstances, including among those with cirrhosis and among...

BMS has resubmitted an application to the FDA for approval of daclatasvir, this time in combination with Sovaldi (sofosbuvir), to treat genoty...